Kiniksa Pharmaceuticals Ltd. Class A (KNSA)
NASDAQ:KNSA
Want to see KNSA full AI Analyst Report?
KNSA Stock Chart & Stats
$44.90
$0.18(0.88%)
At close: 4:00 PM EST
$44.90
$0.18(0.88%)
Day’s Range― - ―
52-Week Range$26.27 - $59.87
Previous CloseN/A
Volume84.12K
Average Volume (3M)757.40K
Market Cap
$3.61B
Enterprise Value$3.46B
Total Cash (Recent Filing)$468.09M
Total Debt (Recent Filing)$9.03M
Price to Earnings (P/E)50.1
Beta0.40
Next Earnings
Jul 28, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.98
Shares Outstanding46,303,276
10 Day Avg. Volume574,612
30 Day Avg. Volume757,404
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)5.39
Price to Sales (P/S)4.52
P/FCF Ratio120.45
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue4.58
Enterprise Value/Gross Profit8.39
Enterprise Value/Ebitda34.04
Forecast
1Y Price Target
$64.00Price Target Upside42.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.37
Revenue Forecast (FY)$936.62M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained operating and free cash flow near reported earnings provides durable financial flexibility to fund commercialization, R&D and potential M&A without heavy reliance on external capital. This reduces dilution risk and supports multi-quarter execution on product uptake and pipeline programs.
ARCALYST Commercial MomentumRapid, repeatable revenue growth and quarter-over-quarter improvement reflect expanding prescriber adoption and patient starts, indicating a scalable commercial model. Durable demand for a chronic therapy supports predictable recurring revenue and leveragable SG&A investments over the next several quarters.
Advancing Pipeline With Near-term MilestonesClear, time-bound clinical milestones reduce long-horizon uncertainty and could extend market exclusivity and product portfolio breadth. Successful Phase II/III progression enables once-monthly dosing commercialization and supports longer-term revenue growth beyond ARCALYST.
Bears Say
Low Patient AwarenessA large awareness gap means the company must sustain high marketing and patient-identification spend to convert the addressable population. This increases customer-acquisition cost and compresses incremental gross margins, requiring several quarters of consistent investment to materially lift penetration.
Quarterly Gross-to-net VariabilityVolatile gross-to-net and co-pay dynamics make revenue recognition and margin forecasting less predictable, requiring larger reserves and more conservative guidance. Persistent variability can strain operating leverage and complicate capital allocation decisions across commercialization and R&D.
Clinical Dose/timing UncertaintyDependence on Phase II dose selection creates material program risk: delays or ambiguous results could push back Phase III starts and commercialization timelines, increasing development costs and delaying value creation from an expanded product offering.
Kiniksa Pharmaceuticals News
KNSA FAQ
What was Kiniksa Pharmaceuticals Ltd. Class A’s price range in the past 12 months?
Kiniksa Pharmaceuticals Ltd. Class A lowest stock price was $26.27 and its highest was $59.87 in the past 12 months.
What is Kiniksa Pharmaceuticals Ltd. Class A’s market cap?
Kiniksa Pharmaceuticals Ltd. Class A’s market cap is $3.61B.
When is Kiniksa Pharmaceuticals Ltd. Class A’s upcoming earnings report date?
Kiniksa Pharmaceuticals Ltd. Class A’s upcoming earnings report date is Jul 28, 2026 which is in 53 days.
How were Kiniksa Pharmaceuticals Ltd. Class A’s earnings last quarter?
Kiniksa Pharmaceuticals Ltd. Class A released its earnings results on Apr 28, 2026. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.202 by $0.068.
Is Kiniksa Pharmaceuticals Ltd. Class A overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals Ltd. Class A’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals Ltd. Class A pay dividends?
Kiniksa Pharmaceuticals Ltd. Class A does not currently pay dividends.
What is Kiniksa Pharmaceuticals Ltd. Class A’s EPS estimate?
Kiniksa Pharmaceuticals Ltd. Class A’s EPS estimate is 0.31.
How many shares outstanding does Kiniksa Pharmaceuticals Ltd. Class A have?
Kiniksa Pharmaceuticals Ltd. Class A has 46,303,276 shares outstanding.
What happened to Kiniksa Pharmaceuticals Ltd. Class A’s price movement after its last earnings report?
Kiniksa Pharmaceuticals Ltd. Class A reported an EPS of $0.27 in its last earnings report, beating expectations of $0.202. Following the earnings report the stock price went up 23.481%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals Ltd. Class A?
Currently, no hedge funds are holding shares in KNSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kiniksa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.00 (42.54% Upside)
$64.00 (42.54% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.37%
12-Months-Change
Fundamentals
Return on Equity
13.26%
Trailing 12-Months
Asset Growth
37.70%
Trailing 12-Months
Company Description
Kiniksa Pharmaceuticals Ltd. Class A
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
KNSA Company Deck
KNSA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: strong Q1 commercial performance with 56% YoY ARCALYST revenue growth, raised full-year guidance, expanding collaboration profit, improved net income, and healthy cash generation. Commercial execution (new prescribers and patient enrollments) and a targeted DTC initiative underpin future growth. The pipeline also showed clear near-term milestones (KPL-387 dose data in H2 2026, Phase III start by year-end, and KPL-1161 Phase I planned). Offsetting items include gross-to-net/ co-pay variability, higher operating expenses tied to growth investments, remaining low patient awareness (requiring continued marketing investment), and the need to confirm Phase II dose selection for KPL-387. Overall, the positives significantly outweigh the challenges.View all KNSA earnings summariesKNSA Stock 12 Month Forecast
Average Price Target
$64.00
▲(42.54% Upside)
Technical Analysis
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Centessa Pharmaceuticals
―
CG Oncology, Inc.
―
Ownership Overview
9.13% Insiders
21.91% Mutual Funds
36.29% Other Institutional Investors
22.46% Public Companies and
Individual Investors